No fast way to eighth place for Incyte
Retifanlimab gets knocked back by a US adcom. Could a rival now beat it to become the eighth anti-PD-(L)1 to reach the US market?
SITC 2020 – second chances for Merck & Co and Oncosec
Among late-breaking abstracts whose titles have just gone live two mechanisms have a chance to redeem themselves.
A handful of huge gains stand out among mid and small-cap biotechs
Drug makers from across the globe feature in 2019’s list of best performing small biotech stocks, from Galapagos to Daiichi Sankyo to Arrowhead.
Japanese drugmakers stand out at the nine-month mark
Daiichi Sankyo’s incredible stock market performance stands out amid the usual mixed bag of fallers and risers among biopharma’s mid- and small caps.
Topsy turvy times for industry’s mid and small cap stocks in the first quarter
What was up is now down as smaller biotech stocks deal with clinical trial failure and acquisitions.
